What's new? Log in Free sign up

argenx SE (ARGX)

Company Profile

Company profile

Ticker

ARGX

Exchange

Website

CEO

Mr. Timothy Van Hauwermeiren EMBA, M.Sc.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE ...

Former names

[object Object]

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

ARGX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$659.42

Low target

$606.00

High target

$723.00

Evercore ISI Group

Truist Securities

Market Outperform

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Current report (foreign)

First and only NMPA-approved treatment for patients with CIDP in China

CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

PRICE T ROWE ASSOCIATES INC /MD/

PRICE T ROWE ASSOCIATES INC /MD/

Artisan Partners Limited Partnership

PRICE T ROWE ASSOCIATES INC /MD/

Artisan Partners Limited Partnership

Financial summary

Financial statements Chart ARGX financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from argenx SE earnings reports.

Institutional ownership, Q2 2024

ARGX institutional ownership history Ownership history

58.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	334	291	+14.8%
Opened positions	83	42	+97.6%
Closed positions	40	89	-55.1%
Increased positions	116	110	+5.5%
Reduced positions	91	102	-10.8%

13F shares	Current	Prev Q	Change
Total value	11.30 tn	8.39 tn	+34.6%
Total shares	34.24 mm	29.43 mm	+16.4%
Total puts	429.00 k	122.40 k	+250.5%
Total calls	302.30 k	170.60 k	+77.2%
Total put/call ratio	1.4	0.7	+97.8%

Largest owners	Shares	Value	Change
T. Rowe Price	5.60 mm	$2.41 bn	+1.7%
FMR	3.53 mm	$1.52 tn	+7.9%
Artisan Partners Limited Partnership	3.51 mm	$1.51 tn	+10.1%
JHG Janus Henderson	2.47 mm	$1.06 tn	NEW
T. Rowe Price Investment Management	1.92 mm	$827.70 mm	-9.0%
Capital World Investors	1.51 mm	$650.11 bn	-18.9%
Avoro Capital Advisors	1.24 mm	$532.59 bn	0.0%
BLK BlackRock	1.01 mm	$434.90 bn	-3.4%
MS Morgan Stanley	819.84 k	$352.57 bn	+18.2%
BLVGF Bellevue	691.87 k	$297.53 bn	-14.7%

Largest transactions	Shares	Bought/sold	Change
JHG Janus Henderson	2.47 mm	+2.47 mm	NEW
Citadel Advisors	653.09 k	+653.09 k	NEW
Holocene Advisors	425.61 k	+425.61 k	NEW
Massachusetts Financial Services	0.00	-425.55 k	EXIT
Capital World Investors	1.51 mm	-353.10 k	-18.9%
Artisan Partners Limited Partnership	3.51 mm	+321.48 k	+10.1%
Alkeon Capital Management	300.00 k	+300.00 k	NEW
BAC Bank of America	290.20 k	+290.20 k	NEW
FMR	3.53 mm	+257.96 k	+7.9%
IVZ Invesco	201.47 k	-217.68 k	-51.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $723

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $639 to $723.

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.

Looking Into argenx's Recent Short Interest

Oppenheimer Reiterates Outperform on argenx, Raises Price Target to $675

Press releases

From Benzinga Pro

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab's deep expertise developing innovative treatments across a broad range of

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx to Participate at Upcoming Investor Conferences

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.